August 28, 2012
Sanofi-aventis announced on August 24 that its antiplatelet drug Plavix (clopidogrel) obtained approval for an additional indication of acute coronary syndrome (ST-segment elevated myocardial infarction (STEMI)) in patients who are treated with percutaneous coronary artery intervention (PCI). STEMI is categorized...read more